426 related articles for article (PubMed ID: 26436865)
1. Distinct modulation of allergic T cell responses by subcutaneous vs. sublingual allergen-specific immunotherapy.
Schulten V; Tripple V; Aasbjerg K; Backer V; Lund G; Würtzen PA; Sette A; Peters B
Clin Exp Allergy; 2016 Mar; 46(3):439-48. PubMed ID: 26436865
[TBL] [Abstract][Full Text] [Related]
2. Short-term subcutaneous grass pollen immunotherapy under the umbrella of anti-IL-4: A randomized controlled trial.
Chaker AM; Shamji MH; Dumitru FA; Calderon MA; Scadding GW; Makatsori M; Jones I; He QA; Subramanian KK; Arm JP; Durham SR; Schmidt-Weber CB
J Allergy Clin Immunol; 2016 Feb; 137(2):452-461.e9. PubMed ID: 26531865
[TBL] [Abstract][Full Text] [Related]
3. Immunological comparison of allergen immunotherapy tablet treatment and subcutaneous immunotherapy against grass allergy.
Aasbjerg K; Backer V; Lund G; Holm J; Nielsen NC; Holse M; Wagtmann VR; Würtzen PA
Clin Exp Allergy; 2014 Mar; 44(3):417-28. PubMed ID: 24734285
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of serum IgG4 antibodies specific to grass pollen allergen components in the follow up of allergic patients undergoing subcutaneous and sublingual immunotherapy.
Rossi RE; Monasterolo G; Coco G; Silvestro L; Operti D
Vaccine; 2007 Jan; 25(5):957-64. PubMed ID: 17045368
[TBL] [Abstract][Full Text] [Related]
5. Subcutaneous and Sublingual Immunotherapy in a Mouse Model of Allergic Asthma.
Hesse L; Nawijn MC
Methods Mol Biol; 2017; 1559():137-168. PubMed ID: 28063043
[TBL] [Abstract][Full Text] [Related]
6. Subcutaneous immunotherapy suppresses Th2 inflammation and induces neutralizing antibodies, but sublingual immunotherapy suppresses airway hyperresponsiveness in grass pollen mouse models for allergic asthma.
Hesse L; Brouwer U; Petersen AH; Gras R; Bosman L; Brimnes J; Oude Elberink JNG; van Oosterhout AJM; Nawijn MC
Clin Exp Allergy; 2018 Aug; 48(8):1035-1049. PubMed ID: 29752757
[TBL] [Abstract][Full Text] [Related]
7. Allergen-specific CD4+ T cell responses in peripheral blood do not predict the early onset of clinical efficacy during grass pollen sublingual immunotherapy.
Bonvalet M; Moussu H; Wambre E; Ricarte C; Horiot S; Rimaniol AC; Kwok WW; Horak F; de Beaumont O; Baron-Bodo V; Moingeon P
Clin Exp Allergy; 2012 Dec; 42(12):1745-55. PubMed ID: 23181790
[TBL] [Abstract][Full Text] [Related]
8. Methods for Experimental Allergen Immunotherapy: Subcutaneous and Sublingual Desensitization in Mouse Models of Allergic Asthma.
Hesse L; Petersen AH; Nawijn MC
Methods Mol Biol; 2021; 2223():295-335. PubMed ID: 33226602
[TBL] [Abstract][Full Text] [Related]
9. Two year follow-up of immunological response in mite-allergic children treated with sublingual immunotherapy. Comparison with subcutaneous administration.
Antúnez C; Mayorga C; Corzo JL; Jurado A; Torres MJ
Pediatr Allergy Immunol; 2008 May; 19(3):210-8. PubMed ID: 18399897
[TBL] [Abstract][Full Text] [Related]
10. Altered chromatin landscape in circulating T follicular helper and regulatory cells following grass pollen subcutaneous and sublingual immunotherapy.
Sharif H; Acharya S; Dhondalay GKR; Varricchi G; Krasner-Macleod S; Laisuan W; Switzer A; Lenormand M; Kashe E; Parkin RV; Yi Y; Koc M; Fedina O; Vilà-Nadal G; Marone G; Eifan A; Scadding GW; Fear DJ; Nadeau KC; Durham SR; Shamji MH
J Allergy Clin Immunol; 2021 Feb; 147(2):663-676. PubMed ID: 33160969
[TBL] [Abstract][Full Text] [Related]
11. Lack of detectable alterations in immune responses during sublingual immunotherapy in children with seasonal allergic rhinoconjunctivitis to grass pollen.
Rolinck-Werninghaus C; Kopp M; Liebke C; Lange J; Wahn U; Niggemann B
Int Arch Allergy Immunol; 2005 Feb; 136(2):134-41. PubMed ID: 15650310
[TBL] [Abstract][Full Text] [Related]
12. Pretreatment IgE sensitization patterns determine the molecular profile of the IgG4 response during updosing of subcutaneous immunotherapy with timothy grass pollen extract.
Schmid JM; Würtzen PA; Dahl R; Hoffmann HJ
J Allergy Clin Immunol; 2016 Feb; 137(2):562-70. PubMed ID: 26141262
[TBL] [Abstract][Full Text] [Related]
13. Heterogeneity of antibody responses among clinical responders during grass pollen sublingual immunotherapy.
Baron-Bodo V; Horiot S; Lautrette A; Chabre H; Drucbert AS; Danzé PM; Sénéchal H; Peltre G; Galvain S; Zeldin RK; Horak F; Moingeon P
Clin Exp Allergy; 2013 Dec; 43(12):1362-73. PubMed ID: 24261946
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of subcutaneous and sublingual immunotherapy with grass allergens for seasonal allergic rhinitis: a meta-analysis-based comparison.
Di Bona D; Plaia A; Leto-Barone MS; La Piana S; Di Lorenzo G
J Allergy Clin Immunol; 2012 Nov; 130(5):1097-1107.e2. PubMed ID: 23021885
[TBL] [Abstract][Full Text] [Related]
15. Real-life compliance and persistence among users of subcutaneous and sublingual allergen immunotherapy.
Kiel MA; Röder E; Gerth van Wijk R; Al MJ; Hop WC; Rutten-van Mölken MP
J Allergy Clin Immunol; 2013 Aug; 132(2):353-60.e2. PubMed ID: 23651609
[TBL] [Abstract][Full Text] [Related]
16. Sublingual grass pollen immunotherapy is associated with increases in sublingual Foxp3-expressing cells and elevated allergen-specific immunoglobulin G4, immunoglobulin A and serum inhibitory activity for immunoglobulin E-facilitated allergen binding to B cells.
Scadding GW; Shamji MH; Jacobson MR; Lee DI; Wilson D; Lima MT; Pitkin L; Pilette C; Nouri-Aria K; Durham SR
Clin Exp Allergy; 2010 Apr; 40(4):598-606. PubMed ID: 20184605
[TBL] [Abstract][Full Text] [Related]
17. One-year evaluation of clinical and immunological efficacy and safety of sublingual versus subcutaneous allergen immunotherapy in allergic conjunctivitis.
Sayed KM; Kamel AG; Ali AH
Graefes Arch Clin Exp Ophthalmol; 2019 Sep; 257(9):1989-1996. PubMed ID: 31209565
[TBL] [Abstract][Full Text] [Related]
18. Recombinant allergen-based monitoring of antibody responses during injection grass pollen immunotherapy and after 5 years of discontinuation.
Gadermaier E; Staikuniene J; Scheiblhofer S; Thalhamer J; Kundi M; Westritschnig K; Swoboda I; Flicker S; Valenta R
Allergy; 2011 Sep; 66(9):1174-82. PubMed ID: 21480924
[TBL] [Abstract][Full Text] [Related]
19. Grass tablet sublingual immunotherapy downregulates the TH2 cytokine response followed by regulatory T-cell generation.
Suárez-Fueyo A; Ramos T; Galán A; Jimeno L; Wurtzen PA; Marin A; de Frutos C; Blanco C; Carrera AC; Barber D; Varona R
J Allergy Clin Immunol; 2014 Jan; 133(1):130-8.e1-2. PubMed ID: 24290282
[TBL] [Abstract][Full Text] [Related]
20. An evidence-based analysis of house dust mite allergen immunotherapy: a call for more rigorous clinical studies.
Calderon MA; Casale TB; Nelson HS; Demoly P
J Allergy Clin Immunol; 2013 Dec; 132(6):1322-36. PubMed ID: 24139829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
